Abstract: Processes for making and using compounds of formula (I): wherein R1, R2, R3, R4a, R4b, R5 and R6 are defined herein, as well as other indene derivatives are disclosed herein. These compounds are disclosed as being useful in treating inflammatory conditions or diseases.

Abstract: The present invention relates to methods for reconstituting and relates to reconstitution devices suitable for reconstituting many different materials. Furthermore, the present invention includes methods of treatment and methods of use related to a reconstitution device or apparatus. Some embodiments are suitable for reconstituting small amounts of a pharmaceutical compositions and using the pharmaceutical composition for the treatment of sexual dysfunction.

Abstract: The invention provides retinoic acid receptor (RAR) selective agonists and formulations thereof for the treatment of disease or for inducing a medically beneficial effect.

Abstract: The invention relates to a cosmetic composition comprising, in a physiologically acceptable aqueous medium, a cucurbic acid compound of formula (I) in which R1 represents a radical COOR3, R3 denoting a hydrogen atom or a C1-C4 alkyl radical, optionally substituted with one or more hydroxyl groups; R2 represents a hydrocarbon-based radical containing from 1 to 18 carbon atoms; a homopolymer of a monomer comprising a sulfonic group; and a crosslinked acrylic acid homopolymer. Use for caring for and making up keratin materials.

Abstract: Described herein are topical oil-based formulations that find use in the treatment of alopecia, i.e., hair loss, and in the promotion of hair growth.

Abstract: Provided herein are small molecules for the induction of fibroblast proliferation and increased secretion or production of proteins. The small molecules described herein can be used for the promotion of skin regeneration. Also provided herein are methods for promoting skin regeneration and wound healing.

Abstract: The current application is directed to cosmetic methods for changing the appearance of eyes by causing a retraction of the eyelids so that the eyes appear to be more open and have a wider appearance. Various methods involve application of one or more prostaglandins, synthetic prostaglandins, including synthetic prostaglandin F, and synthetic prostaglandin analogues, to eyelids, which results in contraction of eyelid muscles and a wider, more open appearance of the eyes.

Abstract: Compositions and methods for the treatment of premature ejaculation are provided wherein a composition comprising a topical anesthetic, a shear-thinning polymeric thickener, a lipophilic component that is selected from the group consisting of an aliphatic C1 to C8 alcohol, an aliphatic C8 to C30 ester, a liquid polyol and a mixture thereof, water and a buffer system that provides a buffered pH value for the composition in the range of about 3 to about 7.4 is administered to the penile meatus.

Abstract: Embodiments described herein are directed to prostanoid (IP) receptor agonist compounds, including cicaprost and certain prodrugs, and methods of preparation and use for the same. Certain embodiments are directed to the use of cicaprost and certain prodrugs in the treatment of topical and ocular conditions.

Abstract: The present invention relates to compositions, such as bimatoprost, latanoprost and travoprost, and methods to reduce fat in the body of an individual, for example, by topical administration, injection, and/or implantation of such compositions.

Abstract: Disclosed herein is method of treating glaucoma or ocular hypertension comprising administering a prostaglandin agonist and a second therapeutically active agent to a mammal in need thereof, wherein said second therapeutically active agent is selected from: ?-Blockers, Adrenergic Agonists, non-selective adrenergic agonists, ?2-selective adrenergic agonists, Carbonic Anhydrase Inhibitors, Cholinergic Agonists, direct acting cholinergic agonists, chlolinesterase inhibitors, Glutamate Antagonists, Ca2+ channel blockers, Prostamides, Prostaglandins, Cannabinoids, and combinations thereof. Compositions and medicaments containing a combination of these two active agents are also disclosed.

Abstract: We have discovered that p63 inhibition results in increased cellular proliferation. We have also performed a screen for agents capable of increasing cellular proliferation, (e.g., of stem cells such as skin-derived precursors (SKPs)). The invention therefore invention provides compositions, methods, and kits for increasing proliferation of cells, using compounds that decrease p63 expression or activity or using the compounds described herein. The invention also features methods of using these compounds for increasing hair growth, improving skin health, or promoting skin repair in a subject.

Abstract: The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient.

Abstract: Compositions, kits and methods for treating leukemia in a subject (e.g., human) include a first anti-cancer drug consisting of: ?12-prostaglandin J3 or a derivative thereof, or a prostaglandin D receptor (DP) agonist. The compositions may further include a second anti-cancer drug. ?12-prostaglandin J3 is a stable metabolite of omega-3 fatty acid, eicosapentaenoic acid (EPA), and was discovered to have anti-leukemic properties. ?12-prostaglandin J3 was shown to be highly effective in eradicating the leukemia stem cells (LSC) in two murine models of leukemia, thus increasing the survival of the mice. DP agonists were shown to induce apoptosis of human primary Acute Myelogenous Leukemia cells and may be used in compositions, kits and methods for treating leukemia in a subject. The compositions, kits and methods may be particularly useful for treating human subjects who are resistant to one or more anti-cancer drugs.

Abstract: Compositions and methods for the treatment of vasospasm are provided comprising applying an amount of a semi-solid vasoactive prostaglandin composition to the affected tissue. Also provided are methods of improving microcirculation in a replanted body part.

Abstract: Compositions and methods for the treatment of vasospasm are provided comprising applying an amount of a semi-solid vasoactive prostaglandin composition to the affected tissue. Also provided are methods of improving microcirculation in a replanted body part.

Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.

Abstract: The present invention provides an ophthalmic solution without an antimicrobial preservative. The solution includes as an active substance at least one prostaglandin and as a solubilizing agent, a surfactant, where the solubilizing agent is polyoxyl-15-hydroxystearate.

Abstract: An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in a elementary osmotic pump delivery system and at least one release enhancing agent.

Abstract: The present invention relates to novel methods, compositions and kits useful for the treatment of pulmonary diseases such as pulmonary arterial hypertension. In particular, aerosolisable compositions of iloprost are provided which are for use in inhalation therapy. Their administration is by bolus inhalation, which is patient-friendly, effective, and well tolerated. Bolus inhalation may, for example, be achieved using an efficient nebuliser based on the vibrating mesh technology.

Abstract: The specification discloses compositions and methods for treating a soft tissue defect of an individual.

Abstract: Compositions and methods for the treatment of vasospasm are provided comprising applying an amount of a semi-solid vasoactive prostaglandin composition to the affected tissue. Also provided are methods of improving microcirculation in a replanted body part.

Abstract: Lipoxin A4 and its analogs have been discovered to promote the cell proliferation of cornea endothelial cells, and thus promote the proper functioning of the labile tissue layer of cornea endothelial cells. These lipoxin compounds can be administered alone or in combination with other known compounds as a solution that can be topically administered to decrease the swelling of the cornea or maintain the clarity of the cornea. Lipoxin A4 or its analogs can also be combined with other known nutritive compounds to form a solution for storage of a cornea prior to transplantation.

Abstract: The present invention provides methods for producing a non ?-keto peracid that has lower toxicity and lower corrosivity. The present embodiments also provide methods and compositions for reducing microbes on a surface, methods and compositions for preventing and reducing infectious vegetative bacteria on a substrate, and methods and compositions for treating a wound. In particular, compositions of the invention provide for a mixture of an ?-keto peracid and a non ?-keto peracid that works synergistically to reduce microbes on a surface, to prevent vegetative bacteria on a surface and to heal a wound in animals or humans.

Abstract: The specification discloses compositions and methods for treating a soft tissue defect of an individual.

Abstract: The present specification discloses compositions and methods of transplanting tissue useful for treating a soft tissue condition of an individual.

Abstract: The present specification discloses compositions and methods for use in breast augmentation procedures. The compositions include adipose tissue and compounds that upregulate both FGF-2 and VEGF, promote new blood vessel formation thereby reducing tissue volume loss and increasing survival rate of the adipose tissue when the composition is introduced into breast tissue.

Abstract: An object of the present invention is to provide a stable aqueous pharmaceutical composition which suppresses degradation of prostaglandin F2? in a preparation containing prostaglandin F2?. The object was attained by formulating a prostaglandin F2? derivative into an oil-in-water emulsion together with an oil, for example, medium chain fatty acid triglyceride, a water-soluble polymer and water.

Abstract: The invention relates to inhibition of ornithine aminotransferase (OAT) for suppression of tumor cells proliferation. More particularly, the invention relates to methods of treatment of proliferative disorders by the selective inhibition of OAT, and further provides the use of OAT inhibitors, specifically, 5-amino-1,3-hexadienyl-carboxylic acid (Gabaculine), and Gabaculine analogue 8, for compositions and methods for the treatment of proliferative disorders such as hepatocellular carcinoma. The invention further provides methods and kits for the diagnosis of a pathologic proliferative disorder in a mammalian subject, based on determining the level of OAT expressed in a biological sample obtained from a subject.

Abstract: The present invention relates to an aqueous ophthalmic preparation comprising a PGF2? analogue and at least one polyvinyl alcohol and the use thereof for the treatment of glaucoma and ocular hypertension.

Abstract: The hydrocortisone derivative of formula (I), whose IUPAC name is 3-[3,5-Dihydroxy-3-(2-hydroxy-acetyl)-3a,6-dimethyl-7-oxo-dodecahydro-cyclo-penta[alpha]naphthalen-6-yl]-propionic acid, designated as Deina®, is used in the treatment of atrophic tissues, particularly skin, cartilage, connective, and mucosal tissues and scalp skin.

Abstract: The invention relates to a cosmetic composition comprising, in a physiologically acceptable aqueous medium, a cucurbic acid compound of formula (I) in which R1 represents a radical COOR3, R3 denoting a hydrogen atom or a C1-C4 alkyl radical, optionally substituted with one or more hydroxyl groups; R2 represents a hydrocarbon-based radical containing from 1 to 18 carbon atoms; a homopolymer of a monomer comprising a sulfonic group; and a crosslinked acrylic acid homopolymer. Use for caring for and making up keratin materials.

Abstract: The present invention relates to the novel use of prostacyclin analogs for prevention and/or treatment of capillary leakage during surgery. The treatment of the present invention mediates discrete or minimal effects on haemostasis and vasodilation. Thus the present invention provides prostacyclin and analogs thereof for treatment which prevents capillary leakage while minimizing the risk of bleeding. The present invention further provides pharmaceutical compositions and kits of parts comprising prostacyclin or analogs thereof, and methods for treatment.

Abstract: Disclosed herein are compositions comprising an amide related to a prostaglandin and a biogenic amine. Other aspects relate to certain chemical compounds, pharmaceutical compositions, and methods of treating glaucoma.

Abstract: The present invention relates to an ophthalmic solution comprising a prostaglandin compound and viscosity-increasing compound. The ophthalmic solution of the invention is excellent in stability and can provide long lasting and increased effect when administrated topically to the eyes of a patient.

Abstract: Disclosed is a drug delivery system for delivering a drug at a sustained constant rate for a long period, which can be transplanted into an affected part safely and in a simple manner and can deliver a drug to the affected part for a long period. Specifically disclosed is a sustained drug delivery system in which an implant is implanted into a body, wherein the implant is a PEG capsule comprising a box-shaped PEG and a porous PEG sheet.

Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

Abstract: The present invention provides a novel fatty acid derivative. The present invention also provides a method for treating schizophrenia in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a fatty acid derivative.

Abstract: Membrane transporter-targeted therapeutic agents and methods of making and using the same.

Abstract: This invention concerns an ophthalmic solution including: at least one prostaglandin; a solubilizing agent; a gelling agent of the carbomer type; a carbomer polymerization-inhibiting agent; a co-gelling/co-solubilizing agent.

Abstract: There is provided a fat emulsion which has a pH of 4.5 to 6.0 and includes a prostaglandin compound, an oil ingredient, a lecithin, the content of which is 0.15 times or more by mass the content of the oil ingredient, a water-soluble acid having a pKa of 4.0 to 6.0 and having a dissociable group or a salt thereof, and water; and a fat emulsion which includes a prostaglandin compound, an oil ingredient, a lecithin, the content of which is 500 to 5,000 times by mass the content of the prostaglandin compound and is 0.5 to 10 times by mass the content of the oil ingredient, and water, and in which the content of a higher fatty acid is 0.06 times or less by mass the content of the lecithin.

Abstract: A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.

Abstract: Compositions and methods for the treatment of vasospasm are provided comprising applying an amount of a semi-solid vasoactive prostaglandin composition to the affected tissue. Also provided are methods of improving microcirculation in a replanted body part.

Abstract: Disclosed herein are materials and methods for treating patients that have been exposed to pathological levels on ionizing radiation. These materials and methods include administering to a patient in thereof at least one dose of a compound such as prostaglandin (PGE2) as soon as possible after the patient has been exposed to the radiation. Additional embodiments include treating a patient exposed to radiation with at least one dose of a compound that modulates PGE2 activity such as non-steroidal anti-inflammatory compound. Some methods include a first step of administering PGE2 or another compound that binds as soon as possible after exposure to radiation followed by a delayed dosing with at least one compound such as meloxicam that interferes with PGE2 activity.

Abstract: Cosmetic or pharmaceutical compositions comprising compounds of formula (I) and the corresponding salts thereof: wherein: R1 is a radical chosen from —COOR?, —CONR?R?, —CH2OR?, —COR?, —CH2R?, —SO2OR?, —PO3R?R? and —NHR?, wherein R? and R?, which may be identical or different, are defined herein; —R2 is chosen from saturated and unsaturated, linear, branched and cyclic hydrocarbon radicals comprising from 1 to 18 carbon atoms which are optionally substituted by from 1 to 5 identical or different entities chosen from —OR??, —OCOR??, —SR??, —SCOR??, NR??R??, —NHCOR??, halogen, —CN, —COOR?? and —COR??, wherein R?? and R??, which may be identical or different, are defined herein; as well as the use of these compounds, for example, to promote skin desquamation, to stimulate epidermal renewal and/or to combat the signs of skin ageing.

Abstract: Disclosed is a method for treating macular degeneration in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a 15-keto-prostaglandin compound such as 13,14-dihydro-15-keto-20-ethyl-prostaglandin F2? isopropyl ester.

Abstract: Disclosed herein are methods and compositions for replenishing injured and/or damaged cardiomyocytes in a subject by inducing, increasing, and/or enhancing the differentiation of endogenous stem and progenitor cells in the subject.

Abstract: The invention relates to a cosmetic composition in oil-in-water emulsion form comprising a cucurbic acid compound of formula (I) in which R1 represents a radical COOR3, R3 denoting H or a C1-C4 alkyl radical, optionally substituted with one or more hydroxyl groups; R2 represents a hydrocarbon-based radical containing from 1 to 18 carbon atoms; an inulin bearing hydrophobic ester or carbamate groups, an oily phase and an aqueous phase. Use for caring for and making up keratin materials.

Abstract: Cosmetic or pharmaceutical compositions comprising compounds of formula (I) and the corresponding salts thereof: wherein: R1 is a radical chosen from —COOR?, —CONR?R?, —CH2OR?, —COR?, —CH2R?, —SO2OR?, —PO3R?R? and —NHR?, wherein R? and R?, which may be identical or different, are defined herein; R2 is chosen from saturated and unsaturated, linear, branched and cyclic hydrocarbon radicals comprising from 1 to 18 carbon atoms which are optionally substituted by from 1 to 5 identical or different entities chosen from —OR??, —OCOR??, —SR??, —SCOR??, NR??R??, —NHCOR??, halogen, —CN, —COOR?? and —COR??, wherein R?? and R??, which may be identical or different, are defined herein, as well as the use of these compounds, for example, to promote skin desquamation, to stimulate epidermal renewal and/or to combat the signs of skin ageing.

Abstract: The invention relates to a cosmetic composition comprising, in a physiologically acceptable aqueous medium, a cucurbic acid compound of formula (I) in which R1 represents a radical COOR3, where R3 denotes H or a C1-C4 alkyl radical, which is optionally substituted by one or more hydroxyl groups; R2 represents a hydrocarbon radical having from 1 to 18 carbon atoms; and a copolymer of 2-acrylamido-2-methylpropanesulphonic acid and hydroxylated C2-C4 alkyl (meth)acrylate. Application to the care and make-up of keratin materials.